The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Frank Takkinen - Lake Street Capital Markets - Analyst
: Thanks for questions. Congrats on all of the progress. Was hoping to start with one on the mix of sales versus placements in the quarter, obviously,
really impressive placement quarter. Nick, can you maybe talk a little bit more about the mix of how much of those were actual upfront sales versus
placements? And then how the prospects look to get those into a full purchase? Or did they stay as placement and just develop a big recurring
revenue stream?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, LNSR.OQ - Q2 2024 LENSAR Inc Earnings Call
Question: Frank Takkinen - Lake Street Capital Markets - Analyst
: Got it. That makes sense. And then maybe shifting over to manufacturing capacity. Clearly, you're scaling well, and I think I asked about this last
quarter, too, but do you still feel confident you are able to produce the amount of ALLY systems required to keep up with demand now that you're
entering a couple of geographies?
Question: Frank Takkinen - Lake Street Capital Markets - Analyst
: Nice. And maybe just the last one. Help us with back half expectations. I heard the comment, Q2, Q4 typically the strongest. But maybe if you can
help us think about how we should be thinking about our models for Q2 and Q4 and bridging to the expectation for 20% growth for this year?
Question: Frank Takkinen - Lake Street Capital Markets - Analyst
: Yeah, that's helpful. Thanks. Congrats on progress.
Question: Ryan Zimmerman - BTIG, LLC - Analyst
: Hey, guys, good morning and congrats on all the approvals of (inaudible) I wanted to ask about your OUS strategy a little bit, Nick. So just talk to
us how you're thinking about approaching the market. I mean, obviously you have distributors there but is there something beyond just attendance
at clinical meetings? Are you putting any resources in these markets? Just help us understand how you're thinking about approaching that?
Question: Ryan Zimmerman - BTIG, LLC - Analyst
: Great color. And I appreciate that. I want to ask, I mean, last quarter, if I recall, you weren't building the contribution from international revenue. I
think I heard you correctly say that the backlog of 17 is all US. So just want to understand, are you expecting some revenue in the back half of this
year, internationally?
Question: Ryan Zimmerman - BTIG, LLC - Analyst
: Very helpful. And then maybe two more questions from me and I'll hop back in queue. But just you guys accelerated your growth 16% against a
13% comp in the US, great to see. What's your read, Nick, on the health of the procedure environment, particularly for cataracts right now, both
US and globally?
And then the second question I'll just ask upfront. Tom, as we think about margins. I appreciate the guidance this year, conceivably with all the
consumable revenue and recurring revenue next year, margins could step up a little more materially, just help us think about maybe the longer-term
margin opportunity for you guys. Thanks for taking the questions.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, LNSR.OQ - Q2 2024 LENSAR Inc Earnings Call
Question: Ryan Zimmerman - BTIG, LLC - Analyst
: Yeah. First question, Nick, was US accelerated 16% on --
Question: Ryan Zimmerman - BTIG, LLC - Analyst
: Yeah, just your read on cataract procedure -- health of the procedures.
Question: Ryan Zimmerman - BTIG, LLC - Analyst
: Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, LNSR.OQ - Q2 2024 LENSAR Inc Earnings Call
|
